SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Bio-Techne Corporation (TECH) trades at a trailing P/E of 104.5, forward P/E of 29.6. Trailing earnings yield is 0.96%, forward earnings yield 3.38%. PEG 0.09 (Peter Lynch undervalued ≤1.0). Graham Number is $12.29.
Criteria proven by this page:
- VALUE (27/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 104.5); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY 0.96%).
- Forward P/E 29.6 (down from trailing 104.5) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.09 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 0.96% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 3.38% as earnings recover.
- Analyst consensus target $69.33 (+18.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 64/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
27/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TECH
Valuation Multiples
P/E (TTM)104.5
Forward P/E29.6
PEG Ratio0.09
Forward PEG0.09
P/B Ratio4.21
P/S Ratio7.00
EV/EBITDA38.2
Per Share Data
EPS (TTM)$0.52
Forward EPS (Est.)$1.98
Book Value / Share$12.90
Revenue / Share$7.80
FCF / Share$1.43
Yields & Fair Value
Earnings Yield0.96%
Forward Earnings Yield3.38%
Dividend Yield0.59%
Graham Number$12.29
SharesGrow IV$27.22 (-53.6%)
Analyst Target$69.33 (+18.2%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
40.1 |
-9.77 |
4.77 |
8.40 |
1.14% |
| 2017 |
56.7 |
-2.21 |
4.61 |
7.79 |
1.08% |
| 2018 |
44.2 |
0.72 |
5.14 |
8.62 |
0.87% |
| 2019 |
82.3 |
-3.46 |
6.78 |
11.07 |
0.61% |
| 2020 |
44.0 |
0.33 |
7.30 |
13.66 |
0.48% |
| 2021 |
124.3 |
-3.16 |
11.16 |
18.74 |
0.28% |
| 2022 |
50.0 |
0.55 |
7.99 |
12.30 |
0.37% |
| 2023 |
45.0 |
9.73 |
6.52 |
11.29 |
0.39% |
| 2024 |
67.2 |
-1.64 |
5.46 |
9.74 |
0.45% |
| 2025 |
110.4 |
-1.97 |
4.22 |
6.64 |
0.62% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.70 |
$499.02M |
$104.48M |
20.9% |
| 2017 |
$0.52 |
$563M |
$77.29M |
13.7% |
| 2018 |
$0.82 |
$642.99M |
$125.35M |
19.5% |
| 2019 |
$0.62 |
$714.01M |
$96.07M |
13.5% |
| 2020 |
$1.45 |
$738.69M |
$229.3M |
31% |
| 2021 |
$0.87 |
$931.03M |
$140.41M |
15.1% |
| 2022 |
$1.66 |
$1.11B |
$272.05M |
24.6% |
| 2023 |
$1.76 |
$1.14B |
$285.26M |
25.1% |
| 2024 |
$1.05 |
$1.16B |
$168.11M |
14.5% |
| 2025 |
$0.46 |
$1.22B |
$73.4M |
6% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$1.98 |
$1.94 – $2.05 |
$1.22B |
$1.21B – $1.23B |
8 |
| 2027 |
$2.19 |
$2.04 – $2.30 |
$1.3B |
$1.28B – $1.33B |
8 |
| 2028 |
$2.55 |
$2.25 – $2.79 |
$1.44B |
$1.44B – $1.44B |
3 |
| 2029 |
$3.03 |
$2.98 – $3.08 |
$1.53B |
$1.51B – $1.55B |
1 |
| 2030 |
$3.15 |
$3.10 – $3.21 |
$1.71B |
$1.69B – $1.73B |
1 |
